<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388722</url>
  </required_header>
  <id_info>
    <org_study_id>MONITOR</org_study_id>
    <nct_id>NCT04388722</nct_id>
  </id_info>
  <brief_title>Monitoring Noninvasively for Infusion and Transfusion Optimization</brief_title>
  <official_title>Monitoring Noninvasively for Infusion and Transfusion Optimization in a Randomized (MONITOR) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masimo Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masimo Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, cluster randomized controlled trial to assess the effects of an&#xD;
      optimized intraoperative fluid and blood management strategy on postoperative complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor's decision to withdraw study.&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative complication</measure>
    <time_frame>7 days</time_frame>
    <description>Occurrence of at least one post-operative complication by day 7 after surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Post Operative Hemorrhage</condition>
  <condition>Transfusion Related Complication</condition>
  <condition>Blood Transfusion Associated Adverse Reactions</condition>
  <condition>Hypovolemia</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulse CO-Oximeter Sensor</intervention_name>
    <description>Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).</description>
    <arm_group_label>Investigational Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older at the time of consent.&#xD;
&#xD;
          -  Ability to provide written informed consent.&#xD;
&#xD;
          -  Scheduled for non-urgent major surgery with general anesthesia&#xD;
&#xD;
          -  At least one finger available and accessible for performing non-invasive pleth&#xD;
             variability index (PVi) and hemoglobin (SpHb) monitoring.&#xD;
&#xD;
          -  The Attending surgeon, attending anesthesiologist and the clinical care team agree&#xD;
             with enrollment in the study, including the restrictions on monitoring procedures&#xD;
             defined in the control group.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated or uncontrolled hypertension defined as mean arterial pressure (MAP) greater&#xD;
             than 120 mmHg, despite medications.&#xD;
&#xD;
          -  Chronic kidney disease with glomerular filtration rate &lt;30 ml/min/1.73 m2 or requiring&#xD;
             renal-replacement therapy for end-stage renal disease.&#xD;
&#xD;
          -  Surgeries where no bleeding is expected to occur (i.e., total knee surgery where blood&#xD;
             loss is prevented by use of tourniquet).&#xD;
&#xD;
          -  Surgeries performed in the prone position.&#xD;
&#xD;
          -  Acute cardiovascular event, including acute or decompensated heart failure and acute&#xD;
             coronary syndrome.&#xD;
&#xD;
          -  Aortic pathology that could lead to misinterpretation of hemodynamic variables (e.g.&#xD;
             intra- aortic balloon pump, thoracic aorta aneurysm).&#xD;
&#xD;
          -  Renal vascular surgery.&#xD;
&#xD;
          -  Preoperative sepsis.&#xD;
&#xD;
          -  Circulatory shock.&#xD;
&#xD;
          -  Preoperative vasoactive substance infusion before study entry.&#xD;
&#xD;
          -  Concurrent participation in any interventional study.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients who refuse to receive blood transfusion(s).&#xD;
&#xD;
          -  Patients with Do Not Resuscitate (DNR) orders.&#xD;
&#xD;
          -  Open chest surgeries.&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Patients for whom monitoring of CO, SV, PPV, and/or SVV to guide GDT or similar&#xD;
             intra-operative fluid management, including continuous SpHb monitoring, would be&#xD;
             standard of care.&#xD;
&#xD;
          -  Patients have skin abnormalities affecting the digits such as psoriasis, eczema,&#xD;
             angioma, scar tissue, burn, fungal infection, substantial skin breakdown, nail polish&#xD;
             or acrylic nails that would prevent the proper fit and application of the sensors.&#xD;
&#xD;
          -  Cardio-pulmonary bypass (CPB) surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transfusion Reaction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

